PharmaEssentia announced that it had received marketing approval from the United Arab Emirates for Ropeginterferon alfa-2b (Ropeg, or P1101) for the treatment of Polycythemia Vera (PV) at an approved dose of 250 µg/0.5 mL. 

PharmaEssentia has recently submitted its application for listing to the Stock Exchange of Hong Kong (SEHK), and if it passes the scrutiny, it will be officially listed on the OTC next year. In the first three quarters, the company's revenue was mainly generated from the sales of Ropeginterferon alfa-2b in the U.S., with a cumulative revenue of NT$3.46 billion, a 69.5% increase year-on-year.

Ropeg is an innovative, long-acting interferon developed by PharmaEssentia, and is the first drug approved by the U.S. FDA for use in PV patients regardless of whether or not they have previously received other treatments. To date, Ropeg has been approved for use in adult PV patients by the European Union, the U.S., Japan, Taiwan, Switzerland, Israel, South Korea, Macao, the Kingdom of Bahrain, Qatar, and the United Arab Emirates. With the increase in the number of countries where Ropeg is available and the approval of its price, the international market for Ropeg will gradually expand in the future.